William Blair Begins Coverage on LENZ Therapeutics (NASDAQ:LENZ)

William Blair began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report released on Monday, MarketBeat Ratings reports. The firm issued an outperform rating on the stock. William Blair also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.74) EPS, Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($2.10) EPS and FY2025 earnings at ($2.95) EPS.

LENZ has been the topic of a number of other research reports. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a research report on Wednesday, March 27th. They set an overweight rating and a $28.00 target price on the stock. Citigroup initiated coverage on shares of LENZ Therapeutics in a report on Wednesday, April 10th. They set a buy rating and a $34.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of Buy and an average target price of $31.33.

LENZ Therapeutics Trading Down 11.1 %

Shares of NASDAQ LENZ opened at $17.70 on Monday. LENZ Therapeutics has a 12 month low of $14.07 and a 12 month high of $29.82. The company has a market capitalization of $147.30 million, a price-to-earnings ratio of -1.13 and a beta of 0.20.

Insider Buying and Selling

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. purchased 998,009 shares of the stock in a transaction on Thursday, March 21st. The shares were purchased at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the acquisition, the director now directly owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The transaction was disclosed in a document filed with the SEC, which is available at this link. 38.40% of the stock is owned by company insiders.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.